BFA
PVLA

BlackRock Fund Advisors’s Palvella Therapeutics PVLA Stock Holding History

BlackRock Fund Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$99K Buy
877
+9
+1% +$1.11K ﹤0.01% 3613
2016
Q3 		$127K Sell
868
-9
-1% -$1.2K ﹤0.01% 3574
2016
Q2 		$113K Buy
+877
New +$134K ﹤0.01% 3640

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

BlackRock Fund Advisors's PVLA Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Palvella Therapeutics (PVLA) stake by 1% in Q4 2016, buying an estimated $1.11K and bringing the position to 877 shares worth $99K. The position accounts for ﹤0.01% of the portfolio, ranked #3613.

BlackRock Fund Advisors first reported a position in PVLA in Q2 2016 and has held it in 3 quarters since. The position peaked at $127K in Q3 2016. 24 funds tracked by Wall St. Rank hold PVLA as of Q4 2016.

  • BlackRock Fund Advisors held 877 shares of Palvella Therapeutics worth $99K as of Q4 2016.
  • BlackRock Fund Advisors bought 9 Palvella Therapeutics shares in Q4 2016, an estimated $1.11K.
  • Palvella Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3613 holding.
  • BlackRock Fund Advisors first reported a position in Palvella Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Fund Advisors's Palvella Therapeutics position peaked at $127K in Q3 2016.
  • 24 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.